Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

HER2-negative Breast Cancer × sacituzumab govitecan × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 36 Triple Negative Breast Neoplasms 28 Carcinoma, Non-Small-Cell Lung 10 Urinary Bladder Neoplasms 9 Carcinoma, Transitional Cell 9 Neoplasm Metastasis 8 Lung Neoplasms 5 Endometrial Neoplasms 4 Brain Neoplasms 4 Small Cell Lung Carcinoma 3 Glioblastoma 3 Uterine Cervical Neoplasms 2 Salivary Gland Neoplasms 2 Pancreatic Neoplasms 2 Ovarian Neoplasms 2 Esophageal Neoplasms 2 Colorectal Neoplasms 2 Carcinoma, Ovarian Epithelial 2 Advanced Breast Cancer 2 Uterine Neoplasms 1 Urothelial Bladder Carcinoma 1 Triple Negative Locally Advanced Non-resectable Breast Cancer 1 Thyroid Neoplasms 1 Thyroid Carcinoma, Anaplastic 1 Stomach Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Solid Tumor 1 Recurrence 1 Prostatic Neoplasms, Castration-Resistant 1 Prostatic Neoplasms 1

Interventions

eribulin 2 Vinorelbine 2 Paclitaxel 2 Cyclophosphamide 2 trastuzumab deruxtecan 1 taxane 1 sacituzumab govitecan 1 pembrolizumab 1 pamiparib 1 liposomal doxorubicin 1 camrelizumab 1 Precision Medicine 1 Gemcitabine 1 Epirubicin 1 Doxorubicin 1 Docetaxel 1 Cisplatin 1 Carboplatin 1 Capecitabine 1 Anthracyclines 1 Albumin-Bound Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06102824 2024-11-25

ORIENTA

Guangdong Provincial People's Hospital

Phase 2 Recruiting

HER2-negative Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡